Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CBLB | Q13191 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465534 | 0.85 | CHRNA7 (0.38) | IRAK4CHRNA7 | |
| SCHEMBL13058479 | 0.85 | LOX (0.40) | LOXMBOAT4CHRNA7CBLB | |
| SCHEMBL3466819 | 0.82 | CNR2 (0.36) | LOXIRAK4CHRNA7 | |
| SCHEMBL3465578 | 0.81 | LOX (0.41) | LOXIRAK4MBOAT4 | |
| SCHEMBL522063 | 0.77 | CYP1A2 (0.38) | IRAK4TAAR1 | |
| SCHEMBL5547208 | 0.77 | LOX (0.51) | LOXMBOAT4 | |
| SCHEMBL30253319 | 0.72 | NOS3 (0.46) | LOXMBOAT4 | |
| SCHEMBL29073433 | 0.72 | CHRNA7 (0.48) | CHRNA7 | |
| SCHEMBL24736329 | 0.70 | NOS3 (0.48) | IRAK4TAAR1 | |
| SCHEMBL4326351 | 0.70 | NOS3 (0.48) | IRAK4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | LOX 3862/4885IRAK4 548/4885MBOAT4 4636/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | LOX 1735/4885IRAK4 134/4885MBOAT4 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.